Important Deadline Approaches for Shareholders in Altimmune, Inc. Lawsuit

Attention Altimmune, Inc. Shareholders: Legal Notice

The Gross Law Firm has announced a critical reminder for shareholders of Altimmune, Inc. (NASDAQ: ALT). If you purchased ALT shares between August 10, 2023, and June 25, 2025, it's essential you are aware of the impending lead plaintiff deadline on October 6, 2025. This announcement is a call to action for those affected, providing an opportunity for potential lead plaintiffs to step forward and advocate for their rights.

Understanding the Lawsuit

This legal action arises from claims against Altimmune following their announcement on June 26, 2025, regarding the topline results of the IMPACT Phase 2b MASH trial related to Pemvidutide treatment. According to the complaint, the company had created inflated expectations that did not reflect the trial's reality. Specifically, it failed to demonstrate statistically significant results regarding fibrosis reduction, despite claiming a positive trend.

Defendants within the company attributed the unexpected findings to the Phase 2 status of the trial and expressed hopes for better outcomes in the subsequent Phase 3 trial. However, this disappointment led to a drastic drop in the company’s stock price – plummeting 53.2% from $7.71 to $3.61 in just one day, a sharp decline affecting many investors.

Your Next Steps as a Shareholder

As a shareholder, you have the right to participate in this class action and potentially recover losses. While being appointed as a lead plaintiff is not essential to benefit from any settlement, it allows one to take a more active role in the litigation. It is vital to register before the October 6 deadline to ensure your right to recover.

Interested shareholders can register and stay informed through a portfolio monitoring service that will provide updates as the case progresses. Participation is free, allowing you to remain engaged without financial burden.

Why Choose The Gross Law Firm?

The Gross Law Firm is recognized nationally for its commitment to protecting investors' rights. Their focus is on addressing deceit and illegal business practices, advocating for corporate responsibility and transparency. By joining this lawsuit, shareholders can stand against fraudulent practices that impact their investments.

Investors who feel misled by Altimmune’s actions now have an avenue to reclaim losses from this disappointing phase of the company’s development. If you believe you are eligible, don't hesitate to reach out to The Gross Law Firm for assistance. Time is of the essence, and the deadline is fast approaching.